Albis

Albis is a fixed-dose combination therapy developed by Daewoong Pharmaceutical, primarily used for the treatment and prevention of gastric and duodenal ulcers, as well as gastritis. It contains three active ingredients: ranitidine, bismuth potassium citrate, and sucralfate. Ranitidine acts as a histamine H2-receptor antagonist to reduce gastric acid secretion. Bismuth potassium citrate provides cytoprotective effects and possesses antimicrobial activity against *Helicobacter pylori*. Sucralfate forms a physical barrier over ulcerated tissue, protecting it from further damage by acid, pepsin, and bile salts. This combination is designed to provide synergistic effects in acid suppression and mucosal protection. In 2019, Albis was withdrawn from the South Korean market following a regulatory suspension of all ranitidine-containing products due to the detection of N-nitrosodimethylamine (NDMA) impurities.

Brand names

Albis

Other names

Albis Tab